These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22661045)

  • 1. Biological therapy and the immune system in patients with chronic myeloid leukemia.
    Rohon P
    Int J Hematol; 2012 Jul; 96(1):1-9. PubMed ID: 22661045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The biological basis for immunotherapy in patients with chronic myelogenous leukemia.
    Pinilla-Ibarz J; Shah B; Dubovsky JA
    Cancer Control; 2009 Apr; 16(2):141-52. PubMed ID: 19337200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunology and immunotherapy of chronic myeloid leukemia.
    Ilander M; Hekim C; Mustjoki S
    Curr Hematol Malig Rep; 2014 Mar; 9(1):17-23. PubMed ID: 24390549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can increased immunogenicity in chronic myeloid leukemia improve outcomes?
    Chan O; Talati C; Sweet K; Pinilla-Ibarz J
    Expert Rev Hematol; 2019 Apr; 12(4):225-233. PubMed ID: 30855193
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapeutic strategies in chronic myeloid leukemia.
    Clark RE
    Curr Hematol Malig Rep; 2007 May; 2(2):89-94. PubMed ID: 20425356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it?
    Carter BZ; Mak DH; Cortes J; Andreeff M
    Semin Hematol; 2010 Oct; 47(4):362-70. PubMed ID: 20875553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy.
    Rohon P; Porkka K; Mustjoki S
    Eur J Haematol; 2010 Nov; 85(5):387-98. PubMed ID: 20662899
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving outcomes in chronic myeloid leukemia through harnessing the immunological landscape.
    Hsieh YC; Kirschner K; Copland M
    Leukemia; 2021 May; 35(5):1229-1242. PubMed ID: 33833387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment.
    Kong J; Qin YZ; Zhao XS; Hou Y; Liu KY; Huang XJ; Jiang H
    Ann Hematol; 2021 Oct; 100(10):2557-2566. PubMed ID: 34278524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment-free remission and immunity in chronic myeloid leukemia.
    Ureshino H
    Int J Hematol; 2021 May; 113(5):642-647. PubMed ID: 33651270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile.
    Kreutzman A; Rohon P; Faber E; Indrak K; Juvonen V; Kairisto V; Voglová J; Sinisalo M; Flochová E; Vakkila J; Arstila P; Porkka K; Mustjoki S
    PLoS One; 2011; 6(8):e23022. PubMed ID: 21857985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CML vaccines as a paradigm of the specific immunotherapy of cancer.
    Pinilla-Ibarz J; Cathcart K; Scheinberg DA
    Blood Rev; 2000 Jun; 14(2):111-20. PubMed ID: 11012250
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α.
    Alves R; McArdle SEB; Vadakekolathu J; Gonçalves AC; Freitas-Tavares P; Pereira A; Almeida AM; Sarmento-Ribeiro AB; Rutella S
    J Transl Med; 2020 Jan; 18(1):2. PubMed ID: 31900171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.
    Patel AB; O'Hare T; Deininger MW
    Hematol Oncol Clin North Am; 2017 Aug; 31(4):589-612. PubMed ID: 28673390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myeloid leukemia: 2018 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2018 Mar; 93(3):442-459. PubMed ID: 29411417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The interferon-alpha revival in CML.
    Talpaz M; Mercer J; Hehlmann R
    Ann Hematol; 2015 Apr; 94 Suppl 2():S195-207. PubMed ID: 25814086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia.
    Cathcart K; Pinilla-Ibarz J; Korontsvit T; Schwartz J; Zakhaleva V; Papadopoulos EB; Scheinberg DA
    Blood; 2004 Feb; 103(3):1037-42. PubMed ID: 14504104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology of chronic myeloid leukemia: current concepts and future goals.
    Vonka V; Petráčková M
    Expert Rev Clin Immunol; 2015 Apr; 11(4):511-22. PubMed ID: 25728856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antigens in chronic myeloid leukemia: implications for vaccine development.
    Smahel M
    Cancer Immunol Immunother; 2011 Dec; 60(12):1655-68. PubMed ID: 22033582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.